News >

Pembrolizumab/Axitinib Combo Approved in Europe for Frontline RCC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Sep 04, 2019

Thomas Powles, MD, MBBS, MRCP, director of Barts Cancer Centre

Thomas Powles, MD, MBBS, MRCP

The European Commission has approved the combination of pembrolizumab (Keytruda) and axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication